<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01761201</url>
  </required_header>
  <id_info>
    <org_study_id>FLISH-ILT</org_study_id>
    <secondary_id>2010-022302-41</secondary_id>
    <nct_id>NCT01761201</nct_id>
  </id_info>
  <brief_title>&quot;Efficacy and Safety of Levofloxacin vs Isoniazid in Latent Tuberculosis Infection in Liver Transplant Patients&quot;.</brief_title>
  <acronym>FLISH-ILT</acronym>
  <official_title>&quot;A Prospective, Randomized, Comparative Clinical Trial of the Efficacy and Safety of Levofloxacin Versus Isoniazid in the Treatment of Latent Tuberculosis Infection in Liver Transplant Patients&quot;.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fundación Pública Andaluza para la gestión de la Investigación en Sevilla</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Spanish Network for Research in Infectious Diseases</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Fundación Pública Andaluza para la gestión de la Investigación en Sevilla</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A multicenter, prospective, non-inferiority, randomized and open clinical trial comparing
      levofloxacin with isoniazid in the treatment of latent tuberculosis infection in patients
      eligible for liver transplantation.

      Patients over 18 years of age on the waiting list for liver transplantation.

      Sample size: n=870 patients.

      HYPOTHESIS

      Levofloxacin treatment of latent tuberculosis infection, begun while on the waiting list for
      liver transplantation, is safer and not less effective than isoniazid treatment begun after
      transplantation when liver function is stable.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Primary Objective

        1. To demonstrate that the incidence of tuberculosis in patients with latent tuberculosis
           infection and treated with levofloxacin is not higher than that observed in patients
           treated with isoniazid.

           Secondary Objective

        2. To demonstrate that the efficacy of levofloxacin is not limited by adverse effects,
           paying particular attention to hepatotoxicity.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Recruitment rythm not sufficent to reach the simple size needed.
  </why_stopped>
  <start_date>January 2012</start_date>
  <completion_date type="Actual">February 2014</completion_date>
  <primary_completion_date type="Actual">February 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Difference in incidence of tuberculosis disease</measure>
    <time_frame>18 months of follow-up</time_frame>
    <description>A patient will be considered as having tuberculosis when Mycobacterium tuberculosis is isolated by culture or M. Tuberculosis DNA is isolated from a representative clinical sample, organ fluid or tissue by polymerase chain reaction. Also cases of histopathologically confirmed tuberculosis (caseating granulomas with/without demonstration of acid-alcohol resistant bacillus [BAAR]) and clinically compatible presentation will be accepted. Tuberculosis will be classified as pulmonary (pulmonary parenchymal involvement), extrapulmonary (involvement of different organs to the lung) or disseminated (involvement of at least two non-contiguous organs). Cases where tuberculosis is diagnosed on the basis of clinical and/or radiology suspicion and for whom the corresponding physician has prescribed a specific treatment will not be accepted.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mortality</measure>
    <time_frame>18 months</time_frame>
    <description>Number of deaths of any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicity</measure>
    <time_frame>During all the 18 months of follow-up</time_frame>
    <description>Occurrence of grade 3 or 4 toxicities according to the grading (severity) scale of the National Cancer Institute Common Toxicity Criteria Version 4.0, NCI-CTC-AE v 4.0.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Retransplantation</measure>
    <time_frame>18 months</time_frame>
    <description>A new liver transplantation during the follow-up</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Graft dysfunction</measure>
    <time_frame>18 months</time_frame>
    <description>Development of advanced graft fibrosis stages 3 and 4</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Transplant rejection</measure>
    <time_frame>18 months</time_frame>
    <description>The occurrence of acute rejection or chronic rejection as per conventional definitions during the follow-up.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Safety</measure>
    <time_frame>18 months</time_frame>
    <description>Drug tolerance will be evaluated by a clinical study interview and periodic analytical determinations which will include levels of transaminases (ALT and AST), alkaline phosphatase and gamma-GT, bilirubin, according to the study visit schedule.
All symptoms and laboratory results will be evaluated for severity according to the grading (severity) scale of the National Cancer Institute Common Toxicity Criteria Version 3.0, NCI-CTC-AE v 3.0.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">68</enrollment>
  <condition>Latent Tuberculosis Infection</condition>
  <condition>Infection in Solid Organ Transplant Recipients</condition>
  <arm_group>
    <arm_group_label>levofloxacin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Levofloxacin 500 mg daily for 9 months starting on the waiting list for liver transplant</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Isoniazid</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Isoniazid 300 mg/day for 9 months beginning after transplantation, when the &quot;liver function is stable&quot; and not before 3 months nor after 6 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Levofloxacin</intervention_name>
    <description>Levofloxacin</description>
    <arm_group_label>levofloxacin</arm_group_label>
    <other_name>Generic name: Levofloxacin</other_name>
    <other_name>ATC Code: J01MA.</other_name>
    <other_name>Pharmaceutical form: Levofloxacin 500 mg film-coated tablets</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Isoniazid</intervention_name>
    <description>300 mg/day for 9 months beginning after transplantation, when the &quot;liver function is stable&quot; and not before 3 months nor after 6 months.</description>
    <arm_group_label>Isoniazid</arm_group_label>
    <other_name>Generic name: Isoniazid.</other_name>
    <other_name>ATC Code: J04AC</other_name>
    <other_name>Pharmaceutical form: tablets.</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Liver transplantation candidates with age ≥ 18 years, no clinical or radiological evidence
        of active tuberculosis and negative pregnancy test (if applicable)who must meet one or more
        of the following criteria:

          -  PPD skin test (initial or after a &quot;booster effect&quot;) &gt;5 mm. Alternatively, the
             determination may be made by the interferon gamma (IFN-g) production in PPD-stimulated
             lymphocytes using the Quantiferon-TB or ELISPOT assays.

          -  Past history of tuberculosis not properly treated.

          -  Past history of contact with a patient with active TB.

          -  Chest x-ray consistent with past untreated TB (apical fibronodular lesions, calcified
             solitary nodule, calcified lymph nodes or pleural thickening).

        The patient must give their written informed consent.

        Exclusion Criteria:

          -  Lack of consent to participate in the study.

          -  Intolerance or allergy to levofloxacin or to isoniazid.

          -  Documented contact with tuberculosis resistant to levofloxacin or to isoniazid.

          -  Treatment in the previous month with drugs with potential activity against
             Mycobacterium tuberculosis, (especially quinolones).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Julián de la Torre Cisneros, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Universitario Reina Sofía, Córdoba, Spain</affiliation>
  </overall_official>
  <overall_official>
    <last_name>José M. Aguado, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Hospital Universitario 12 de Octubre, Madrid</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Complejo Hospitalario de Albacete</name>
      <address>
        <city>Albacete</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Infanta Cristina,</name>
      <address>
        <city>Badajoz</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clinic</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Vall d'Hebron</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de Cruces</name>
      <address>
        <city>Bilbao</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Complejo Hospitalario Universitario</name>
      <address>
        <city>Coruña</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Reina Sofía</name>
      <address>
        <city>Córdoba</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital universitario Virgen de las Nieves</name>
      <address>
        <city>Granada</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital 12 de Octubre</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Gregorio Marañón</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Ramón y Cajal</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Puerta de Hierro</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Virgen de la Arrixaca</name>
      <address>
        <city>Murcia</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Carlos Haya</name>
      <address>
        <city>Málaga</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clínica Universitaria de Navarra</name>
      <address>
        <city>Pamplona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Marqués de Valdecillas</name>
      <address>
        <city>Santander</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Virgen del Rocío</name>
      <address>
        <city>Seville</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario La Fe</name>
      <address>
        <city>Valencia</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <link>
    <url>http://www.reipi.org/index.php/es/</url>
    <description>official web site for the Spanish Infectious Disease Network</description>
  </link>
  <reference>
    <citation>Torre-Cisneros J, Doblas A, Aguado JM, San Juan R, Blanes M, Montejo M, Cervera C, Len O, Carratala J, Cisneros JM, Bou G, Muñoz P, Ramos A, Gurgui M, Borrell N, Fortún J, Moreno A, Gavalda J; Spanish Network for Research in Infectious Diseases. Tuberculosis after solid-organ transplant: incidence, risk factors, and clinical characteristics in the RESITRA (Spanish Network of Infection in Transplantation) cohort. Clin Infect Dis. 2009 Jun 15;48(12):1657-65. doi: 10.1086/599035.</citation>
    <PMID>19445585</PMID>
  </reference>
  <reference>
    <citation>Aguado JM, Herrero JA, Gavaldá J, Torre-Cisneros J, Blanes M, Rufí G, Moreno A, Gurguí M, Hayek M, Lumbreras C, Cantarell C. Clinical presentation and outcome of tuberculosis in kidney, liver, and heart transplant recipients in Spain. Spanish Transplantation Infection Study Group, GESITRA. Transplantation. 1997 May 15;63(9):1278-86. Review. Erratum in: Transplantation 1997 Sep 27;64(6):942.</citation>
    <PMID>9158022</PMID>
  </reference>
  <verification_date>August 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 3, 2013</study_first_submitted>
  <study_first_submitted_qc>January 3, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 4, 2013</study_first_posted>
  <last_update_submitted>August 5, 2014</last_update_submitted>
  <last_update_submitted_qc>August 5, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 6, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Prophylaxis</keyword>
  <keyword>Tuberculosis</keyword>
  <keyword>Transplant recipients</keyword>
  <keyword>Transplant waiting list</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Tuberculosis</mesh_term>
    <mesh_term>Latent Tuberculosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Levofloxacin</mesh_term>
    <mesh_term>Ofloxacin</mesh_term>
    <mesh_term>Isoniazid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

